Study identifier:D6970C00008
ClinicalTrials.gov identifier:NCT06344104
EudraCT identifier:N/A
CTIS identifier:N/A
A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension
Uncontrolled Hypertension
Phase 3
No
Baxdrostat, Placebo
All
300
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 2 mg baxdrostat 2 mg baxdrostat administered orally, once daily (QD) | Drug: Baxdrostat Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: • 1 mg per tablet for 1mg baxdrostat Arm • 2 mg per tablet for 2mg baxdrostat Arm Other Name: CIN-107 |
Experimental: 1 mg baxdrostat 1 mg baxdrostat administered orally, once daily (QD). | Drug: Baxdrostat Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: • 1 mg per tablet for 1mg baxdrostat Arm • 2 mg per tablet for 2mg baxdrostat Arm Other Name: CIN-107 |
Placebo Comparator: placebo Placebo administered orally, once daily (QD) | Drug: Placebo Placebo tablet administered orally, once daily (QD). |